UroGen Pharma Files 2024 Annual Report Amendment

Ticker: URGN · Form: 10-K/A · Filed: 2025-04-30T00:00:00.000Z

Sentiment: neutral

Topics: amendment, annual-report, pharmaceutical

TL;DR

UroGen Pharma filed its amended 2024 10-K. Check for updates.

AI Summary

UroGen Pharma Ltd. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated April 30, 2025, provides updated information for the company, which is incorporated in Israel and has its principal executive offices in Princeton, NJ.

Why It Matters

This amendment provides updated financial and operational information for UroGen Pharma Ltd. for the fiscal year 2024, which is crucial for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — This filing is an amendment to a standard annual report, indicating it's an update rather than a new event.

Key Numbers

Key Players & Entities

FAQ

What specific changes or updates are detailed in this 10-K/A amendment?

The filing is an amendment to the annual report for the fiscal year ended December 31, 2024, but the specific details of the amendments are not provided in the header information.

When was the original 10-K filed for the fiscal year ended December 31, 2024?

The filing header indicates this is an amendment (10-K/A) to the report for the fiscal year ended December 31, 2024, filed as of April 30, 2025. The original filing date is not explicitly stated but would precede this amendment.

What is UroGen Pharma Ltd.'s primary business sector?

UroGen Pharma Ltd. is in the Pharmaceutical Preparations sector, with SIC code 2834.

Where are UroGen Pharma Ltd.'s principal executive offices located?

The principal executive offices are located at 400 Alexander Park, Princeton, NJ 08540.

What is the significance of the filing date of April 30, 2025?

The filing date of April 30, 2025, indicates when this amendment to the annual report was submitted to the SEC.

From the Filing

0001437749-25-013839.txt : 20250430 0001437749-25-013839.hdr.sgml : 20250430 20250430160034 ACCESSION NUMBER: 0001437749-25-013839 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250430 DATE AS OF CHANGE: 20250430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UroGen Pharma Ltd. CENTRAL INDEX KEY: 0001668243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38079 FILM NUMBER: 25894727 BUSINESS ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 BUSINESS PHONE: 972 9 770 7601 MAIL ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 10-K/A 1 urgn20241231_10ka.htm FORM 10-K/A urgn20231231_10ka.htm 0001668243 true FY 2024 0001668243 2024-01-01 2024-12-31 iso4217:USD 0001668243 2024-06-28 xbrli:shares 0001668243 2025-04-23   --12-31FY2023       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 10-K/A   (Amendment No. 1)       (Mark One) ☑   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934     For the fiscal year ended December 31 , 2024       OR     ☐   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934     For the transition period from_____________ to ________________   Commission file number: 001-38079     UROGEN PHARMA LTD.   (Exact name of registrant as specified in its charter)     Israel   98-1460746 (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification Number) 400 Alexander Park , Princeton , NJ   08540 (Address of principal executive offices)   (Zip Code)       Registrant ’ s telephone number, including area code:   ( 646 ) 768-9780   Securities registered pursuant to Section 12(b) of the Act:     Title of each class Trading Symbol Name of exchange on which registered Ordinary Shares, par value NIS 0.01 per share URGN The Nasdaq Stock Market LLC   Securities registered pursuant to Section 12(g) of the Act: None       Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☑   Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☑   Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐   Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.   Large accelerated filer ☐   Accelerated filer ☐ Non-accelerated filer ☑   Smaller reporting company ☑  

View on Read The Filing